Renovion has enrolled the first patient in a Phase III trial of ARINA-1, which is designed to prevent the progression of bronchiolitis obliterans syndrome (BOS) in patients with a bilateral lung transplant.

The study will assess the safety and efficacy of the investigational nebulised therapy ARINA-1 in around 100 individuals across 15 US sites.

Renovion chief medical officer Marty Zamora said: “ARINA-1 has the potential to be implemented early in pulmonary function decline in patients who are experiencing early signs of BOS. It has a strong safety profile and poses minimal risk to an unstable patient population.

“Today, there are no FDA-approved therapies to treat patients at the point of this initial drop in lung function.

“This Phase III NDA-enabling trial is an important step in our efforts to provide patients with a safe and effective potential therapy to treat a drop in lung function more proactively.”

ARINA-1 restores lung health by clearing mucus and helps in reducing airway inflammation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is also planning to initiate trials of ARINA-1 for treating chronic inflammatory airway diseases, including non-tuberculous mycobacteria-pulmonary disease and non-cystic fibrosis bronchiectasis.

The off-label therapies that are used for the treatment of BOS, the most common form of chronic lung allograft dysfunction, are showing serious side effects like infections.

Within five years of a lung transplant, around 50% of all lung transplant patients are developing BOS.